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INTRODUCTION 
Malignant gliomas are the most common and deadly type of 
adult brain tumours. Brain tumour initiating cells (BTICs), a 
type of cancer stem cell, have been identified to contribute to 
the tumourigenesis and recurrence of gliomas. Surrounding 
BTICs in situ are monocytoid cells, which are innate immune 
cells of the central nerve system (CNS) (microglia) or cells 
which have infiltrated into the CNS (macrophages). Though 
thought to be initially recruited to eradicate the tumours, these 
cells are ultimately exploited by the tumour cells to promote 
their own growth. Thus, activating or reprogramming 
monocytoid cells may represent an approach to curb BTIC 
growth. Previously, a drug screen of 1040 compounds for their 
capacity to further activate lipopolysaccharide (LPS)-
stimulated human microglia identified niacin, orlistat, 
bumetanide and meclocycline as hits [1]; demeclocycline was 
subsequently added to the list. 
METHODS 
Human adult and fetal microglia and human blood monocytes 
were plated at 50,000 cells/well/100μL and 100,000 
cells/well/100μL, respectively, in 96-well plates, and 
transferred to BTIC medium an hour prior to treatment. 
Treatment involved administering each drug (10 μM) with and 
without LPS (100 ng/mL). Media were collected 48 hrs after 
treatment and termed microglia/monocyte conditioned 
medium (MCM/Mono CM). BTIC cells derived from glioma 
patients were exposed at 10,000 cells/well/100μL with either 
MCM or Mono CM in 96-well plates for 72 hrs. The number 
of neurospheres above 60 microns was counted with the 
assistance of a light microscope (n = 4 per well) for 
neurosphere assay analysis. 
RESULTS 
Microglia-conditioned media (MCM) generated in the 
presence of LPS and each drug attenuated growth of patient-
derived BTICs in vitro when compared to LPS-MCM alone. 
Notably, these drugs also promoted BTIC differentiation into 
cells which exhibited reduced stemness.  A similar effect was 
observed with monocyte-conditioned media (Mono CM) with 
all four drugs in the presence of LPS (Figure 1). Interestingly, 
a combination of demeclocycline and niacin also reduced 
BTIC growth without the need for LPS. 
 
Figure 1. After exposure to Mono CM treated with each drug, 
BTICs exhibited reduced neurosphere formation, both in 
numbers and in size. Representative images are depicted for 
each treatment below the graph (n = 5, bars = ± SEM; 1-way 
ANOVA with posthoc Dunnet comparison, *p<0.05, 
**p<0.01). 
DISCUSSION AND CONCLUSIONS 
This study has verified a number of promising candidates for 
harnessing innate immune cells in the glioma micro-
environment to curb BTIC growth, paving the way for future 
approaches to clinically targeting BTIC growth. Future 
directions could test combinations of drugs with alternatives to 
LPS, such as amphotericin B, a recently observed activator of 
monocytoid cells, and compounds observed endogenously, 
such as interleukin-1β and interferon gamma, which could 
lead to identifying more clinically-viable options. 
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